Last updated on December 2017

Generation 1 Alzheimer’s Risk


Brief description of study

This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype.

 

Other Details:

https://clinicaltrials.gov/ct2/show/NCT02565511

Clinical Study Identifier: TX154939

Contact Investigators or Research Sites near you

Start Over

Janie Krull, Research Clinical Manager

Via Christi Research
Wichita, KS USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.